Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

Older adults living with Type 2 diabetes face more than just blood sugar concerns. New research shows some of the most ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Blue Cross Blue Shield of Massachusetts says it will soon stop covering popular drugs for weight loss, like Ozempic.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The drug helped lower patients’ blood sugar and reduce their weight by an average of 16 pounds.

People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

The state’s largest commercial health insurer will stop covering a popular class of prescription drugs for weight loss, ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.